Objective: This study evaluates the long-term outcomes, biliary complication rates, and risk factors for biliary complications after liver transplantation from "donation after cardiac death" (DCD) donors. Background: Recent enthusiasm toward increased use of DCD donors' livers is mitigated by high biliary complication rates. Predictive risk factors for the development of biliary complications after DCD liver transplantation remain incompletely defined. Methods: We performed a retrospective review of 1157 "donation after brain death" (DBD) and 87 DCD liver transplants performed between January 1, 1993, and December 31, 2008. Patient and graft survivals and complication rates within the first year of transplantation were compared between DBD and DCD groups. Cox proportional hazards models were used to assess the influence of potential risk factors. Results: Patient survival was significantly lower in the DCD group compared with the DBD group at 1, 5, 10, and 15 years (DCD: 84%, 68%, 54%, and 54% vs DBD: 91%, 81%, 67%, and 58%; P < 0.01). Graft survival was also significantly lower in the DCD group compared with the DBD group at 1, 5, 10, and 15 years (DCD: 69%, 56%, 43%, 43% vs DBD: 86%, 76%, 60%, 51%; P < 0.001). Rates of overall biliary complications (OBC) (DCD: 47% vs DBD: 26%; P < 0.01) and ischemic cholangiopathy (IC) (DCD: 34% vs DBD: 1%; P < 0.01) were significantly higher in the DCD group. Donor age [hazard ratio (HR): 1.04; P < 0.01] and donor age greater than 40 years (HR: 3.13; P < 0.01) were significant risk factors for the development of OBC. Multivariate analysis revealed that cold ischemic time (CIT) greater than 8 hours (HR: 2.46; P = 0.05) and donor age greater than 40 years (HR: 2.90; P < 0.01) significantly increased the risk of IC. Conclusions: Long-term patient and graft survival after DCD liver transplantation remain significantly lower but acceptable when compared with DBD liver transplantations. Donor age and CIT greater than 8 hours are the strongest predictors for the development of IC. Careful selection of younger DCD donors and minimization of CIT may limit the incidence of severe biliary complications and improve the successful utilization of DCD donors' livers. (Ann Surg 2011;253:817-825) L iver transplantation remains the standard treatment for patients with end-stage liver disease. Over the years, there have been significant improvements in liver transplant outcomes because of improved surgical techniques, organ preservation, immunosuppression, and anti-infective therapies. This success has resulted in more
patients being listed for transplantation out of proportion to the number of available organs. Thus, the donor-organ shortage remains a significant obstacle to increasing the number of liver transplants. In an attempt to combat the donor-organ shortage, more liver transplant centers are using livers from "donation after car- Despite this increase in DCD liver utilization, there remains reluctance among many centers to aggressively use these organs. This unwillingness is based on both national database and single-center studies reporting inferior patient and graft survival rates when compared to liver transplants from "donation after brain death" (DBD) donors. [1] [2] [3] [4] Another important concern with the use of DCD livers is the development of biliary complications. The incidence of biliary complications after DCD liver transplantation ranges between 25% and 60%, 3, [5] [6] [7] [8] compared with 10% to 30% seen in DBD whole liver transplantation. [9] [10] [11] [12] The most critical biliary complication that frequently requires retransplantation is the development of ischemictype biliary strictures or ischemic cholangiopathy (IC). Ischemic cholangiopathy is defined as intrahepatic or nonanastomotic and extrahepatic biliary strictures in the presence of a patent hepatic artery. The incidence of IC in DCD liver transplantation ranges between 10% and 50% in published series. 5, 6, 8, 13, 14 Although not all patients with IC require retransplantation, this complication can result in considerable patient morbidity, including biliary sepsis, prolonged antibiotic therapy, and the requirement for multiple endoscopic or percutaneous biliary procedures. In addition, most patients with IC maintain excellent hepatocellular function despite biliary damage and dysfunction and therefore have relatively low Model for End-Stage Liver Disease (MELD) scores when being considered for retransplantation. In many cases, requests for a MELD exception are made to the regional review boards to obtain a sufficient MELD score for retransplantation. The granting of these exceptions is quite variable across the country and not standardized in the current liver allocation process. This prolonged waiting time may result in recurrent biliary sepsis, the development of multiresistant organisms, and patient debilitation that can potentially exclude them from retransplantation.
Previous analyses utilizing the United Network for Organ Sharing/Organ Procurement and Transplantation Network Liver Transplantation Registry have identified potential risk factors that are predictive of graft survival after DCD liver transplantation. 15, 16 However, the risk factors for the development of biliary complications were not analyzed in these studies. The objectives of this analysis were to (1) compare the long-term outcomes of DCD and DBD liver transplants with 15-year follow-up, (2) compare the incidence of biliary complications between DCD and DBD liver transplant recipients, and (3) identify potential risk factors for the development of biliary complications in DCD liver transplant recipients at the University of Wisconsin (UW).
METHODS
After the institutional review board approval was attained, a retrospective review of all deceased donors' liver transplants was performed at the UW between January 1993 and December 2008. During that period, 1157 DBD and 87 DCD liver transplants were performed. Patient and graft survivals were assessed by using Kaplan-Meier estimates. Complication rates within the first year of transplantation were compared between DBD and DCD liver transplants. Complications included primary nonfunction (PNF), portal vein thrombosis, hepatic artery stenosis (HAS) and thrombosis, and overall biliary complications (OBC). Biliary complications were then subdivided into the following groups: IC, defined as nonanastomotic biliary strictures with a patent hepatic artery; common bile duct (CBD) leak; CBD anastomotic stricture; the presence of bile duct stones, casts, or sludge; and abscess or biloma formation.
Donor and recipient variables were identified as potential risk factors for the development of biliary complications after DCD liver transplantation. Donor variables included age, warm ischemic time (WIT), cold ischemic time (CIT), weight, and body mass index (BMI). Donor WIT in all DCD donors was defined as the time from extubation until organ flushed with preservative solution. Additional donor physiologic variables that were analyzed included the times at which the donor's systolic blood pressure was less than 70, 60, and 50 mm Hg and the times at which arterial oxygen saturation was less than 70%, 60% and 50%. Recipient variables included age, BMI, and MELD score. Univariate analyses were performed to identify significant risk factors for the development of OBC, IC, and anastomotic CBD strictures. Those variables found to be significant in univariate analysis were then used in multivariate analysis.
Our techniques of organ procurement and preservation during DCD are previously described. 1, 17, 18 In summary, most extrarenal DCD donors were brought to the operating room before the withdrawal of life support. Informed consent was obtained from the next of kin for the placement of femoral arterial and venous cannulas under local anesthesia and the administration of intravenous heparin (10,000-30,000 units) and phentolamine (10-20 mg) before extubation. The phentolamine was given to prevent vasospasm and to facilitate subsequent organ flushing. The patient's physician of record withdrew life support by stopping intravenous medication and extubation. After the withdrawal of support, the patient was monitored with an arterial catheter, continuous electrocardiogram, pulse oximeter, and physical examination. Blood pressure, pulse rate, and blood oxygen saturations were recorded at various time points after withdrawal. Electrocardiographic silence was not required in most instances because the lack of respirations and the lack of a monitored arterial pulse were used as criteria for cessation of cardiopulmonary function.
Five minutes after the declaration of death, cold UW solution was flushed into the femoral arterial cannula and the femoral venous cannula was opened to gravity. Median sternotomy and a midline abdominal incision were made and the intra-abdominal organs were removed en bloc. In those instances where femoral cannulas were not placed, the distal aorta was cannulated immediately on entry into the abdomen. Approximately 1.5 to 3 L of UW solution was administered in situ, and an additional 1 L was used on the back table to flush the portal vein via the superior mesenteric vein and the orifices of the celiac, superior mesenteric, and renal arteries. To minimize arterial ischemia to the bile ducts, tissue plasminogen activator (tPA) was injected into the second liter of aortic UW solution in 12 donors between 2007 and 2008. This was an attempt to minimize potential microthrombi that form in the arteries supplying the biliary tree.
Both the gallbladder and the CBD were irrigated with UW solution. The entire en bloc preparation was stored in UW solution at 4 • C and separated either immediately or on return to our center. Because minimal dissection was performed in situ, approximately 1 to 1.5 hours of additional back-table dissection were required. All livers were transplanted as soon as possible after retrieval. Since June 2005, we have started the recipient operation either before or immediately after the return of the procurement team to minimize CIT.
Before 2007, all patients were considered to be candidates for either DCD or DBD liver transplantation. In 2007, we began obtaining informed consent for DCD livers at the time of the initial evaluation. We now limit DCD liver transplants to consented patients undergoing primary transplants with MELD score greater than 18. We avoid using DCD livers in the setting of retransplantation for chronic allograft failure because of the potential for prolonged CIT seen with difficult transplant hepatectomies.
Throughout the 16 years of performing DCD liver transplants at the UW, the recipient operation has undergone multiple technical modifications. Liver transplants performed between 1993 and 1999 were done with total vena caval replacement and venovenous bypass. Transplants performed after 1999 were performed with the piggyback technique. In the majority of cases, the livers were flushed with chilled lactated ringers and albumin solution through the hepatic artery before reperfusion. To decrease significant post-reperfusion injury, we have recently changed to a 300-mL blood flush through the portal vein and chilled lactated ringers and albumin solution flushed through the hepatic artery before reperfusion. In the majority of the cases, reperfusion of the graft was performed through the portal vein alone and before the hepatic arterial anastomosis. In transplants performed after December 2008, we have stopped adding tPA into the preservative solution and have begun injecting it into the hepatic artery after portal venous reperfusion to maximize enzymatic activity. On the basis of previous reports describing thrombolytic use in DCD liver transplants, 19 we administer 20 mg of TPA diluted in 10-mL normal saline into the hepatic artery. The artery is clamped for 20 minutes and then allowed to back bleed to prevent a large amount of TPA from entering the circulation. Duct-to-duct biliary anastomosis is preferred at our institution. Before 2005, all patients undergoing either DCD or DBD liver transplants received a T-tube that was removed at approximately 3 months after transplant. This practice has changed to all patients receiving a duct-to-duct anastomosis without a stent or T-tube except in the setting of primary sclerosing cholangitis, in which a Roux-en-Y choledochojejunostomy is the preferred method.
Both DBD and DCD liver recipients were screened similarly for arterial or biliary complications after transplantation. All patients, who had a T-tube placed, underwent T-tube cholangiogram on POD 7. If these results revealed no evidence of leak or stricture, the T-tube clamping trials were initiated. When the clamping trials were tolerated, the patient was discharged with the T-tube clamped. T-tubes were removed at 3 months after transplant if a pull-back cholangiogram revealed a mature tract and no evidence of leak. In patients who underwent duct-to-duct anastomosis without a T-tube, Endoscopic Retrograde Cholangiopancreatography was performed selectively on the basis of Liver Function Test abnormalities alone. Hepatic arterial interrogation was performed with duplex ultrasonography on the basis of liver function test abnormalities. If the result of duplex ultrasonography was abnormal, a computed tomographic angiography was performed to assess vessel patency.
Our immunosuppressive protocol was primarily tacrolimus and prednisone, with mycophenolate mofetil or basiliximab added if early postoperative renal dysfunction was present. Rejection episodes were treated with high-dose methylprednisolone, increased tacrolimus dosage, and, when necessary, with either antilymphocyte globulin or OKT3 monoclonal antibody.
STATISTICAL ANALYSIS
Patient and graft survival rates and postoperative complication rates were estimated by using a Kaplan-Meier product limit estimator and compared with the log-rank test. Cox proportional hazards models were used to assess the influence of potential risk factors. Continuous data are presented as mean ± SD. All tests were 2-sided, and a P ≤ 0.05 was considered to be statistically significant. Table 1 . There were no differences in mean donor age, BMI, donor sex, or donor race between the groups. Mean DCD donor weight was significantly higher than DBD donor weight. Significant differences were also seen between the 2 groups with regard to donor cause of death (P < 0.001). A greater percentage of anoxic brain injury was seen in the DCD group (34.7% vs 12.7%), whereas a greater percentage of cerebrovascular accidents were seen in the DBD group (36.2% vs 21.3%).
RESULTS

Comparisons of donor and recipient variables between DCD and DBD groups are listed in
There were no differences in mean recipient age or MELD score between the groups. Recipients of DCD liver had significantly higher mean BMI compared with DBD liver recipients. Significant differences were seen between the 2 groups with regard to recipient diagnosis (P = 0.04). A greater percentage of patients in the DBD group had cholestatic liver disease (22.1% vs 15.0%), whereas a greater percentage of patients with malignant neoplasm were seen in the DCD group (20.7% vs 10.2%).
As expected, mean donor WIT in DCD donors (20.8 ± 9.4 minutes) was significantly longer compared with DBD donors. Mean CIT was significantly longer in DBD (8.3 ± 2.3 hours) compared with DCD liver transplants (7.2 ± 2.3 hours). No differences in PNF, portal vein thrombosis, hepatic artery thrombosis, or HAS were seen between the 2 groups ( Table 2) .
Eighteen patients in the DCD group were found to have hepatocellular carcinoma (HCC) on the basis of liver explant pathology. Fourteen patients had a known diagnosis of HCC and 4 had no evidence of tumor on the basis of preoperative imaging. Twelve (86%) of the 14 patients had tumor sizes that were within Milan criteria. One patient had stage III and 1 had stage IVA1 disease.
Overall patient survival was significantly lower in the DCD group compared with the DBD group at 1, 3, 5, 10, and 15 years (DCD: 84%, 72%, 68%, 54%, 54% vs DBD: 91%, 85%, 81%, 67%, 58%; P < 0.01) ( Fig. 1 ). Graft survival was also significantly lower in the DCD group compared with the DBD group at 1, 3, 5, 10, and 15 years (DCD: 69%, 60%, 56%, 43%, 43% vs DBD: 86%, 80%, 76%, 60%, 51%; P < 0.001) (Fig. 2) .
The estimate of the 1-year retransplant rate was 19.0% in the DCD patients and 4.8% in the DBD patients (P = 0.0001). Ischemic cholangiopathy (81.3%) was the indication for retransplantation in the majority of DCD liver recipients, followed by PNF (12.5%) and portal vein thrombosis (6.2%).
In December 2005, we modified our protocol to start the recipient procedure before the return of the recovery team, provided that the visualization of the liver at the donor hospital confirmed suitability for transplant. This resulted in a significant decrease in mean CIT in DCD transplants from 8.2 hours before December 2005 to 4.9 hours after December 2005. We did not make any changes in acceptable donor age or donor WIT limits. Sixty DCD liver transplants were performed in the former era and 27 were performed in the latter era. There were no differences in patient or graft survival rates or rates of OBC or IC between the 2 DCD groups.
Overall biliary complication rates were significantly higher in the DCD (47%) than in DBD group (26%) ( Table 3 ). Rates of IC were also significantly higher in the DCD liver transplant recipients (34%) than in DBD liver recipients (1%). There were no differences in the rates of CBD anastomotic strictures or CBD leaks between the groups. However, the rates of biliary stones, casts, or sludge and the presence of abscesses or bilomas were significantly higher in the DCD group. The majority of patients with stones, casts, or sludge and bilomas were those with concomitant IC. Figure 3 depicts the Kaplan-Meier estimate for the rate of IC in the first year of transplant.
Eighty-three percent of the diagnoses of IC were made within 120 days of transplant. Of the 24 patients who developed IC within 1 year of transplant, 6 (25%) died without receiving another transplant, 11 (45.8%) underwent retransplantation, and 7 (29.2%) maintained adequate liver function and did not require retransplantation. One patient with IC who was not retransplanted by the endpoint of this study is currently listed for retransplant. Those patients who died without retransplantation were not candidates for retransplantation because of the development of malignancy, extrahepatic sepsis, or a cerebrovascualar accident. Ninety-six percent of the patients who were diagnosed with IC required multiple biliary procedures or studies that included endoscopic cholangiopancreatography, percutaneous transhepatic cholangiography, or T-tube cholangiography for the management of IC. The number of procedures performed in all recipients with IC was variable and dependent on the timing of retransplantation or death. Patients with IC who survived and did not require retransplantation underwent an average of 8.1 ± 6.9 procedures within 1 year of the diagnosis of IC. Univariate analyses were performed to identify risk factors or the development of OBC in DCD liver transplants (Table 4 ). Recipient age and MELD score were not significant risk factors for the development of OBC. Donor age as a continuous variable and donor age greater than 40 years were significant risk factors for the development of OBC. Donor WIT, CIT, weight, and BMI were not found to increase the risk of OBC. Donor physiologic variables were studied as potential risk factors for the development of OBC. Recording of donor blood pressure and oxygen saturations after extubation were monitored in all DCD donors after 2001 (n = 55). The times of donor systolic blood pressure less than 70, 60 and 50 mm Hg and the times of oxygen saturation less than 70%, 60%, and 50% were entered into our analyses. None of these physiologic variables was shown to increase the risk of OBC (data not shown).
The same variables were used in a separate univariate analysis to determine risk factors for the development of IC (Table 5 ). Cold ischemic time greater than 8 hours, donor age as a continuous variable, and donor age greater than 40 years were significant risk factors for the development of IC. Donor WIT and donor physiologic variables, including time of low systolic blood pressure and oxygen saturations, were not significant risk factors for the development of IC. Multivariate analysis for the development of IC was performed on the 2 significant variables in the univariate analysis (Table 6 ). Both CIT greater than 8 hours and donor age greater than 40 years were significant risk factors for developing IC.
A separate univariate analysis using the same donor and recipient variables was performed to study the risk factors for the development of anastomotic biliary strictures (Table 7) . Cold ischemic time, donor WIT, donor age, recipient age, and MELD were not significant risk factors. However, donor weight and donor BMI were significant risk factors for developing anastomotic biliary strictures in the DCD liver recipients. We performed an additional univariate analysis, examining the role of donor weight and donor BMI in the development of anastomotic biliary strictures in DBD liver recipients. Donor BMI as a continuous variable, donor BMI greater than 25 kg/m 2 , and donor weight greater than 82 kg were significant risk factors for the development of biliary anastomotic strictures (Table 8 ). 
DISCUSSION
Because of the continued donor-organ shortage, liver transplantation from DCD donors has been increasing in recent years. Although more centers are transplanting DCD livers, there is a lack of enthusiasm in the transplant community because of inferior outcomes with DCD livers. Reported 1-year and 3-year graft survival rates for DCD liver transplantation range between 67% and 73% and between 56% and 63%, respectively. Most studies comparing DBD and DCD liver transplantation demonstrate significantly worse 1-and 3-year graft survival rates for DCD compared with DBD liver transplantation. 3, 2, 16 However, other single-center studies have demonstrated similar graft survival rates between the 2 groups. 13, 20, 21 A recent single-center analysis of 19 DCD and 234 DBD liver transplants demonstrated no difference in graft survival in recipients without hepatitis C. However, graft survival rates were significantly worse in hepatitis C recipients of DCD and expanded criteria donor (ECD) livers when compared with standard criteria donor livers. 8 This updated analysis of 87 DCD liver transplants reveals significantly lower graft survival compared with that seen in DBD liver transplants. Our 10-year graft survival rate of 43% is similar to that reported by de Vera et al 3 from the University of Pittsburgh. With longer follow-up, we are able to report a 15-year graft survival rate of 43% compared with 51% for DBD liver transplants. It is clear that the differences in graft survival between DCD and DBD liver transplants are greatest within the first year of transplantation and that gap narrows over time. Despite its inferiority to DBD liver transplants, long-term DCD liver graft survival seems acceptable and comparable with DBD liver transplantation.
Reported long-term patient survival rates after DCD liver transplantation are lower than that after DBD liver transplantation, but in multiple studies, the differences are not statistically significant. 2, 3, [20] [21] [22] One-year and 3-year patient survival rates for DCD liver transplantation range between 79% and 89% and between 68% and 81%, respectively. Both our previous analysis 1 and this updated analysis demonstrate significantly lower patient survival in the DCD than in DBD liver recipients. One factor contributing to this difference may be the higher patient survival rates in our DBD liver recipients compared to other single-center studies. 3, 20, 21 The data also suggest the influence of a learning curve in our earlier experiences. An additional analysis of liver transplants performed after 2005 at our institution showed similar patient survival rates between DCD and DBD liver transplant recipients (data not shown).
Our retransplant rate within the first year for DCD liver recipients (19%) was significantly higher than that for DBD liver recipients (4.8%). One must be cautious in interpreting retransplantation rates because those data underestimate true graft failure, as some patients may have died before being retransplanted. Nonetheless, a significantly higher retransplant rate was seen in the DCD group. This observation is similar to other analyses describing higher DCD liver retransplant rates. 23, 24 In our analysis, we did not see any differences in the rates of PNF or hepatic artery thrombosis between DCD and DBD liver recipients, and 81% of the DCD retransplants were for complications of IC. The DCD liver recipients have a low rate of technical failures and usually maintain adequate hepatocellular function despite severe biliary tract damage. On the basis of other analyses, this unique pattern of graft failure leads to significantly longer times before listing for retransplantation and lower MELD scores at retransplantation and limits access to retransplantation for these patients. In addition, these patients have been shown to receive higher-risk livers at retransplantation compared with DBD liver recipients. 23, 24 We agree with these authors that a modification of the allocation system with MELD score exceptions is necessary to truly reflect the severity of disease in these DCD liver recipients so that they are not disadvantaged at the time of retransplantation.
In our previous analysis of 36 DCD liver transplants, we found a significantly higher rate of HAS in the DCD group. 1 These stenoses were all distal to the anastomosis. Because our procurement techniques did not change over time, we hypothesized that the artery might have sustained some ischemic injury secondary to the DCD recovery and implantation process. A recent single-center analysis of 39 DCD liver transplants demonstrated a significantly higher rate of HAS (12.8%) than that in DBD transplants. However, 2 of the 5 strictures were at the arterial anastomosis, so it was difficult to ascertain whether the cause was technical or whether issues related to the DCD allograft itself. With this expanded analysis of 87 DCD liver transplants, we did not find a significant increase in HAS. It remains unclear whether the incidence of HAS is significantly elevated in DCD liver transplants. We are still aggressive in ordering computed tomographic angiograms on any DCD liver recipient with an abnormal hepatic arterial Doppler signal to rule out concomitant HAS.
The development of biliary complications after liver transplantation has been described as the true Achilles' heel of the operation. Although most complications can be treated with endoscopic or percutaneous techniques, some require reoperation and retransplantation. Although many cases of IC lead to retransplantation, not all patients with IC require retransplantation. Lee et al 6 studied 44 patients who developed intrahepatic biliary strictures after DCD liver transplantation and classified the strictures into 4 groups on the basis of cholangiographic appearance: unilateral focal, confluence, bilateral multifocal, and diffuse necrosis. They found that patients who developed unilateral focal, defined as stricture, only in the segmental branch of the unilateral hemiliver, or confluence, defined as several strictures, at the confluence level, had 100% survival and good outcome with or without additional interventions. Patients with bilateral multifocal strictures or diffuse necrosis of the bile ducts had poor prognosis, resulting in either death or retransplantation despite aggressive therapeutic interventions. In our analysis, 65% of patients who developed IC either died or underwent retransplantation and 35% of patients are alive without requiring retransplantation. Those who died without retransplantation developed comorbidities that excluded them from retransplantation. The patients who did not necessitate retransplantation did require multiple biliary procedures to minimize morbidity and maintain allograft function. We agree with Lee et al 6 that less-severe IC can be treated without retransplantation as long as the strictures are few and accessible for endoscopic or percutaneous therapy.
The rates of OBC; IC; the presence of casts, stones and sludge; and abscess and biloma formation were significantly elevated in the DCD versus DBD group. The differences were mostly driven by the presence of IC. Others, who have reported on the incidence of IC in DCD liver transplants, diagnosed all cases of IC within 120 days of transplantation. 13 In our study, 83% of IC diagnoses were made within the first 120 days after transplant. We did see additional diagnoses of IC made beyond 120 days and thus chose to define our complication rate as incidence within 1 year of transplantation. We recommend continued close monitoring for IC out to 1 year after transplantation.
There have been 2 published reports on the identification of risk factors for graft survival after DCD liver transplantation. Mateo et al 16 performed a retrospective review of the United Network for Organ Sharing database and analyzed 367 DCD and 33,111 DBD liver transplants. In addition to identifying recipient risk factors that increased risk of DCD allograft loss, they confirmed that donor WIT greater than 30 minutes and CIT greater than 10 hours negatively impacted graft survival. In addition, donor age and cerebrovascualar accident as donor cause of death increased risk of graft loss. Lee et al 15 used the United Network for Organ Sharing database and identified 874 DCD liver transplants to calculate a DCD risk index. Favorable DCD donor criteria included donor age of 45 years or less, donor WIT 15 minutes or less, and CIT 10 hours or less. Increasing donor age was more highly predictive of poor outcomes in DCD compared with DBD.
Studies examining the risk factors for the development of biliary complications in DCD liver transplantation are limited. Chan et al 13 reviewed 52 DCD liver transplants to identify risk factors for the development of IC. Seven patients (13.7%) in the DCD group developed IC. Donor WIT and total ischemic time were found to be significant risk factors for the development of IC. Donor age and CIT were not found to increase risk of IC. In addition, donor age greater than 50 years, CIT 9 hours or greater, and donor weight greater than 100 kg predicted the development of IC in the DCD group. In contrast, our univariate analysis revealed donor age as a continuous variable and donor age of 40 years or more as the only variables that significantly increased the risk for OBC. Additional univariate and multivariate analyses of the 26 patients with IC revealed donor age, donor age of 40 years and more, and CIT greater than 8 hours as significant risk factors for the development of IC.
It is unclear what the upper age limit should be for DCD liver donors to avoid biliary complications and optimize allograft survival. Our data and other data presented here suggest that a cutoff of between 40 and 50 years would be appropriate. In contrast, a previous report has suggested that the use of livers from selective DCD donors older than 55 years results in similar 1-year graft survival compared with DCD livers from the donors younger than 55 years, provided that the CIT is brief. 25 Another recent report suggests that the use of DCD livers from donors older than 60 years results in similar patient and graft survival compared with both DCD livers transplantation from donors younger than 60 years and DBD liver transplantation. 21 On the basis of our data, donor age is a significant risk factor for the development of both OBC and IC in DCD liver transplant recipients. We currently use 45 years as the upper age limit for DCD liver donors, as we feel that age is the strongest predictor for the development of IC in these recipients.
Recent analyses of DBD liver transplantation have been unable to demonstrate CIT as a risk factor for the development of biliary complications. 9, 11 In contrast, CIT greater than 8 hours in the DCD group resulted in a 2.5 times increased risk for the development of IC. The calculated mean CIT for the entire DCD group was 7.2 hours. We also performed an analysis assessing the effects of changing our protocol in a recent era of transplants to decrease CIT in the DCD liver recipients. Although we had a significant reduction in mean CIT from 8.7 to 4.9 hours, we did not see significant differences in DCD liver recipient outcomes. These data suggest that multiple factors, in addition to CIT, contribute to outcomes, and it is likely that greater numbers are needed to achieve sufficient power for statistical analysis. On the basis of our analyses, we suspect that the bile ducts in DCD livers are more susceptible to ischemia reperfusion injury in the presence of prolonged donor WIT and CIT greater than 8 hours. We, therefore, aim for the shortest CIT possible and CIT of no longer than 8 hours.
It was surprising for us that donor WIT did not impact the development of OBC or IC in our study. This finding is similar to the study by Chan et al, 13 in which donor WIT did not impact the development of IC. As we have consistently kept the definition of donor WIT as the time of extubation to organ flush, we have no explanation for this based on various definitions described in the literature. The main difference between DCD and DBD procurement and transplantation is the presence of donor WIT that occurs before the declaration of death. It seems intuitive that longer donor WIT would result in a higher incidence of biliary complications and, specifically, IC. For that reason, we have been reluctant to expand the donor WIT greater than 30 minutes throughout the history of our program. It is unclear why donor WIT was not significant but CIT was in our study. It may be due to insufficient power of the analysis or because we do not have a sufficient number of prolonged WIT for that to make a difference in the analysis. It is likely that a combination of donor age, CIT, and donor WIT contribute to the development of IC.
Two recent studies have demonstrated that donor postextubation hypotension correlates with poor outcomes after DCD liver transplantation. Chan et al 13 showed that the time at which donor mean arterial blood pressure was less than 35 and 50 mm Hg correlated with significantly increased risk of IC. Ho et al 26 studied 37 DCD liver transplants performed at multiple transplant centers, with organs recovered from the same organ procurement organization (OPO). They identified a composite endpoint of death, PNF, and graft loss within 1 year or diffuse biliary ischemia. Fourteen DCD liver recipients reached the composite endpoint. The study showed that if the time at which the donor systolic blood pressure dropped below 50 mmHg is greater than 15 minutes, there is a statistically higher chance of reaching the composite endpoint. Both studies suggest that the time of profound hemodynamic instability may be a better predictor of subsequent function or injury. On the basis of these studies, we included donor physiologic parameters in our univariate analyses. We had data on 55 DCD donors and were unable to identify any of these parameters as potential risk factors for the development of OBC or IC. We do suggest close monitoring of these variables in all DCD donors. These times may be more helpful in identifying acceptable donors with shorter periods of hypotension or hypoxemia despite longer WIT (defined as times from extubation to organ flush). We currently use donor WIT of 30 minutes as our cutoff, but we feel that this parameter may be expanded if the times of postextubation hypotension are shorter than 15 minutes.
Donor BMI and donor weight were studied in all univariate analyses. Previous reports have suggested that donor weight greater than 100 kg in combination with long total ischemic times and older donor age are predictive risk factors for the development of IC. 13 In our study, these variables did not impact the development of OBC or IC in the DCD donors. However, donor weight and BMI were significant risk factors for the development of anastomotic biliary strictures in the DCD group. We then extended our analysis and studied these variables in the DBD cohort. We found that donor weight and donor BMI were significant risk factors for the development of strictures in the DBD group as well. It seems that the risk of developing of anastomotic biliary strictures because of donor weight or BMI is not unique to the DCD liver. We do not know the mechanism based on this analysis, but we hypothesize that these donors may have more advanced vascular disease that predisposes the liver to ischemic anastomotic strictures. More analyses are needed to elucidate the mechanisms of these risk factors.
It is critical to discuss the disparity of outcomes between DCD and DBD liver transplantation with potential recipients. The decision to accept a DCD liver should be an individual patient's decision after adequate informed consent is obtained. Adequate informed consent needs to include not only patient and graft survival rates but also the morbidity associated with the increased rate of biliary complications. We believe that informed consent is a dynamic process that should start at the initial evaluation and continue periodically during return visits while on the waiting list and at the time of organ offer. If a patient has significant encephalopathy and it is felt that adequate comprehension cannot be attained, it is critical to have the discussion with a family member or power of attorney.
Critical questions that remain include which recipients are good candidates for DCD livers or which recipients gain a survival benefit from receiving a DCD liver versus waiting on the list for a DBD liver. Although we have had an active DCD liver transplant program for more than 16 years, we still do not have sufficient numbers to answer these questions with certainty. Currently, we limit DCD liver transplants to consented patients undergoing primary transplants with MELD score greater than 18. We avoid using DCD livers in the setting of retransplantation for chronic allograft failure because of the potential for increased CIT seen with prolonged transplant hepatectomies. Some have suggested using these livers for patients with HCC outside Milan criteria with low physiologic MELD scores. We do not select this group as sole recipient for DCD livers. In 14 DCD liver recipients with known HCC before transplant, the vast majority (86%) were within Milan criteria. In addition, we have performed DCD liver transplants on patients with PNF, acute liver failure, and high MELD scores.
Some have investigated survival benefit after liver transplantation with the use of high-risk allografts. Amin et al 27 used a Markov decision analytic model to estimate survival benefit of an immediate ECD liver transplant versus waiting for an standard criteria donor liver. In patients with MELD score greater than 20, immediate ECD liver transplant provided a survival benefit despite a higher risk of primary graft failure. A recent study suggested that patients with MELD score greater than 20 attain a survival benefit regardless of the Donor Risk Index, of which DCD liver transplantation is a significant component. 28 Data presented at the Academic Surgical Congress in 2009 also suggested that patients with MELD score greater than 20 receive a survival benefit from receiving a DCD liver compared to waiting for a DBD liver. Subgroup analysis revealed that survival benefit is also dependent upon wait-list time to receiving a DBD liver. 29 Others had demonstrated that critically ill recipients with MELD score greater than 30 at a single center had similar graft survival rate with DCD compared with recipients of DBD liver transplants. 3 In our analysis, MELD score was not found to impact the risk of biliary complications. On the basis of our experience and these recent studies, we feel that higher MELD patients are suitable candidates because of their severity of illness and the higher likelihood of obtaining a survival benefit. We suspect that the lower MELD limit should be approximately 20, but published data at this point is inconclusive to know with certainty the MELD score above which a true benefit is attained. Until more definitive data are available, the MELD cutoff should likely be individualized by center, expertise, potential for retransplantation in the region, and available resources. We hope to expand on our analysis in the future when we have sufficient power to answer these questions.
There are several limitations to our study. Because of its retrospective nature, there is selection bias in the decision to choose certain livers for transplantation and which patients should undergo retransplantation. This bias can have an impact on our results. To have a maximal number of patients for our analysis, we have included all patients since the inception of the program. Previously described technical modifications over time are included, possibly impacting our results. We initially attempted a multivariate analysis using all variables that we felt could likely contribute to the development of biliary complications. Because of the limited number of patients in our study, many of the independent variables were highly correlated and the effects were not well estimated. We, therefore, performed our multivariate analysis on only the variables that were significant on univariate analyses. In addition, we did not include recipient WIT as a potential risk factor for biliary complications because of limited tracking of these times in our database. Others have shown that prolonged recipient WIT, or the time for implantation, may impact liver allograft survival in expanded criteria DBD liver transplants. 30 Total ischemic time has been show to influence the development of IC in DCD liver transplant recipients. 13 We have recently begun to track recipient WIT so that future analyses can include these times as a potential risk factor.
In summary, long-term patient and graft survival after DCD liver transplantation remain significantly lower but acceptable when compared with DBD liver transplants. A significant cause of allograft failure in DCD liver recipients is the development of severe biliary complications, including IC. It is likely that a combination of donor WIT, CIT, and donor age contribute to the development of severe biliary complications. Our data suggest that donor age and CIT are the strongest predictors for the development of IC. Donor WIT does not seem to be a significant risk factor for the development of these complications. Careful selection of younger DCD donors and minimizing CIT may limit the incidence of severe biliary complications and improve the successful utilization of DCD donor livers.
